P361: PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysisECCO'22Year: 2022
Authors: Saifuddin, A.(1);Kent, A.(2);Mehta, S.(3);Hicks, L.(4);Gonzalez, H.(5);Segal, J.(4);Brooks, M.(6);Subramanian, S.(7);Bhala, N.(8);Conley, T.(7);Patel, K.(9);Lamb, C.(10);Walker, G.(11);Kennedy, N.(12);Sebastian, S.(5);
(1)St Mark's Academic Institute, Inflammatory Bowel Disease, London, United Kingdom;(2)King's College Hospital NHS Foundation Trust, Dept of Gastroenterology, London, United Kingdom;(3)Barts Health NHS Trust, Dept of Gastroenterology, London, United Kingdom;(4)Imperial College Healthcare NHS Trust, Dept of Gastroenterology, London, United Kingdom;(5)Hull University Teaching Hospitals NHS Trust, Dept of Gastroenterology, Hull, United Kingdom;(6)The Royal Wolverhampton NHS Trust, Dept of Gastroenterology, Wolverhampton, United Kingdom;(7)Royal Liverpool and Broadgreen University Hospitals NHS Trust, Dept of Gastroenterology, Liverpool, United Kingdom;(8)University Hospitals Birmingham NHS Foundation Trust, Dept of Gastroenterology, Birmingham, United Kingdom;(9)St George's University Hospitals NHS Foundation Trust, Dept of Gastroenterology, London, United Kingdom;(10)Newcastle Hospitals NHS Foundation Trust, Dept of Gastroenterology, Newcastle, United Kingdom;(11)Torbay and South Devon NHS Foundation Trust, Dept of Gastroenterology, Torbay, United Kingdom;(12)Royal Devon and Exeter NHS Foundation Trust, Dept of Gastroenterology, Exeter, United Kingdom;PREPARE-IBD collaborators
P362: Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.ECCO'22Year: 2022
Authors: Fuentes-Valenzuela, E.(1);García-Alonso , F.J.(1); Maroto-Martín , C.(1);Juan-Casamayor , L.(1);Garrote Adrados , J.A.(2);Almendros Muñoz , R.(3);de Prado , Á.(1);Marinero , M.Á.(1);Calleja Carbajosa , R.(1);Vara Castrodeza, A.(4);Barrio , J.(1);
(1)Hospital Universitario Rio Hortega, Gastroenterology Department, Valladolid, Spain;(2)Hospital Universitario Rio Hortega, Department of Laboratory Medicine, Valladolid, Spain;(3)Hospital Universitario Rio Hortega, Department of Pharmacy, Valladolid, Spain;(4)Hospital Universitario Rio Hortega, Radiology Department, Valladolid, Spain;
P363: Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?ECCO'22Year: 2022
Authors: Kim, J.E.(1);Won, H.(2);Kim, Y.H.(1);Kim, E.R.(1);Hong, S.N.(1);Chang, D.K.(1);
(1)Samsung medical center, Department of Medicine, Seoul, Korea- Republic Of;(2)Samsung Medical Center, Biomedical Statistics Center- Research Institute for Future Medicine, Seoul, Korea- Republic Of;Hojeong Won
P364: Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprineECCO'22Year: 2022
Authors: Alborzi Avanaki, F.(1);Moghbel, N.(2);Aletaha, N.(3);E.Daryani, N.(4);Farahvash, M.J.(5);Miroliaii, A.(6);Shayegan, N.(6);Anjidani, N.(7);
(1)Assistants professor of gastroenterology, department of Gastroenterology -Tehran University of Medical Sciences, Teheran, Iran- Islamic Republic Of;(2)Assistant professor of gastroenterology. Kurdistan university of Medical sciences, Gastroenterology, kurdistan, Iran- Islamic Republic Of;(3)Associated professorof Gastroenterology. Tehran University of Medical sciences, Gastroenterology department of Imam Khomeini hospital, Tehran, Iran- Islamic Republic Of;(4)Professor of Gastroenterology.Tehran University of Medical sciences, Gastroenterology Department of Imam khomeini hospital, Tehran, Iran- Islamic Republic Of;(5)Tehran University of Medical Sciences, Gastroenterology Department of Imam Khomeini Hospital, Tehran, Iran- Islamic Republic Of;(6)Tehran University of Medical sciences, Gastroenterology, Tehran, Iran- Islamic Republic Of;(7)Orchid pharmed company, Medical department, Tehran, Iran- Islamic Republic Of;
P365: Weight gain after initiation of adalimumab in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Darwin, L.(1);Wall, C.(2);Su, H.(1);Gearry, R.B.(2);
(1)Canterbury District Health Board, Gastroenterology Department, Christchurch, New Zealand;(2)University of Otago, Department of Medicine, Christchurch, New Zealand;
P366: Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's DiseaseECCO'22Year: 2022
Authors: Häcker, D.(1);Siebert, K.(2);Metwaly, A.(1);Hölz, H.(2);De Zen, F.(2);Köhler, N.(3);Pauling, J.K.(3);Matchado, M.(4);List, M.(4);Schwerd, T.(2);Haller, D.(1,5);
(1)Technical University of Munich, Chair of Nutrition and Immunology, Freising, Germany;(2)Dr. von Hauner Children's Hospital - University Hospital - LMU Munich, Department of Paediatrics, Munich, Germany;(3)LipiTUM - Technical University of Munich, Chair of Experimental Bioinformatics - TUM School of Life Sciences, Freising, Germany;(4)Technical University of Munich, Chair of Experimental Bioinformatics, Freising, Germany;(5)ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany;
P367: quality of life in patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Salem, J.(1);Ghandour, F.(2);Halabi, M.T.(3);Douaihy, T.(1);Matta, J.(4);Bedran, K.(5);Farhat, S.(5);
(1)University of Balamand, Faculty of medicine, Ashrafieh- Beirut, Lebanon;(2)Saint Georges University Medical Center, Pathology, Ashrafieh- Beirut, Lebanon;(3)Saint Joseph University, Faculty of Education, Beirut, Lebanon;(4)Saint Georges University Medical Center, Paediatrics, Ashrafieh- Beirut, Lebanon;(5)Saint Georges University Medical Center, Gastroenterology, Ashrafieh- Beirut, Lebanon;
P370: Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenanceECCO'22Year: 2022
Authors: Panés, J.(1);Loftus, E.V.J.(2);Higgins, P.(3);Lindsay, J.O.(4);Zhou, W.(5);Yao, X.(5);Ilo, D.(5);Phillips, C.(5);Tran, J.(5);Sanchez Gonzalez, Y.(5);Vermeire, S.(6);
(1)Hospital Clinic Barcelona- IDIPABS- CIBERehd- Barcelona- Spain, n/a, Barcelona, Spain;(2)Mayo Clinic College of Medicine, n/a, Rochester, United States;(3)University of Michigan, n/a, Ann Arbor, United States;(4)The Royal London Hospital- Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(5)AbbVie Inc., n/a, North Chicago, United States;(6)University Hospital Leuven, n/a, Leuven, Belgium;
P371: The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study.ECCO'22Year: 2022
Authors: Domènech MoralPhD, E.(1);Llaó, J.(2);Mañosa, M.(1);Martín-Arranz, E.(3);Zabana, Y.(4);Navarro-Llavat, M.(5);Garcia-Planella, E.(6);Busquets, D.(7);Pineda, J.R.(8);Monfort, D.(9);Gutiérrez, A.(10);García-Alonso, F.J.(11);Menchén, L.A.(12);Villoria, A.(13);
(1)Germans Trias i Pujol University Hospital and CIBEREHD, Gastroenterology, Badalona, Spain;(2)Althaia Xarxa Assistencial Universitària de Manresa, Gastroenterology, Manresa, Spain;(3)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(4)Hospital Universitari Mútua Terrassa and CIBEREHD, Gastroenterology, Terrassa, Spain;(5)Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain;(6)Hospital de la santa Creu i Sant Pau, Gastroenterology, Barcelone, Spain;(7)Hospital Universitari Dr. Josep Trueta, Gastroenterology, Girona, Spain;(8)Xerencia Xestión Integrada de Vigo, Gastroenterology, Vigo, Spain;(9)Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain;(10)Hospital General Universitario de Alicante-Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL and CIBEREHD, Gastroenterology, Alicante, Spain;(11)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Samoa;(12)Hospital General Universitario/Instituto de Investigación Gregorio Marañón and CIBEREHD, Gastroenterology, Madrid, Spain;(13)Hospital Parc Taulí and CIBEREHD, Gastroenterology, Sabadell, Spain;on behalf of the CECUM study by GETECCU
P372: Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s diseaseECCO'22Year: 2022
Authors: Aleman Gonzalez, H.(1);Stamp, K.(1);Whitehead, E.(1);Pattinson, A.(1);Turnbull, J.(1);Myers, S.(1);Talbot, A.(1);Sebastian, S.(1);
(1)Hull University Teaching Hospitals, Inflammatory Bowel Disease, Kingston Upon Hull, United Kingdom;
P373: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safetyECCO'22Year: 2022
Authors: Chaparro, M.(1);Acosta, D.(1);Rodríguez, C.(2);Vicuña, M.(2);Mesonero, F.(3);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);Hernández Martínez, Á.(6); Arroyo, M.T.(7);Vera Mendoza, I.(8);Sicilia, B.(9);Muñoz Villafranca, C.(10);Castro-Poceiro, J.(11);Martínez Cadilla, J.(12);Vázquez Morón, J.M.(13);Montil, E.(14);Sierra-Ausín , M.(15);Calafat, M.(16); Leo Carnerero, E.(17);Manceñido Marcos, N.(18);Torrealba M, L.(19); Alonso-Galán, H.(20); Benítez, J.M.(21);Ber Nieto, Y.(22);Cabello Tapia, M.J.(23);Diz-Lois Palomares, M.T.(24);García, M.J.(25);Armesto González, E.M.(26);Calvet Calvo, X.(27);Piqueras, M.(28);Dueñas Sadornil, C.(29); Pérez Calle, J.L.(30);Botella, B.(31); Martínez-Pérez, T.D.J.(32);Ramos, L.(33);Rodríguez-Grau, M.C.(34);Fernández Forcelledo, J.L.(35); Gutiérrez, A.(36);Sesé Abizanda, E.(37);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario de Navarra HUN and Instituto de Investigación Sanitaria de Navarra IdiSNA, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain;(4)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital Clinic of Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBERehd, Gastroenterology Unit, Barcelona, Spain;(6)Hospital Universitario Torrecárdenas, Gastroenterology Unit, Almería, Spain;(7)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(8)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(9)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(10)Hospital de Basurto, Gastroenterology Unit, Basurto, Spain;(11)Hospital Sant Joan Despí-Moisès Broggi, Gastroenterology Unit, Barcelona, Spain;(12)Hospital Álvaro Cunqueiro. Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación en Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS-UVIGO, Gastroenterology Unit, Vigo, Spain;(13)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(14)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(15)Complejo Asistencial Universitario de León, Gastroenterology Unit, León, Spain;(16)Hospital Universitari Germans Trias i Pujol and CIBEREHD, Gastroenterology Unit, Badalona, Spain;(17)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(18)Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario Dr. Josep Trueta, Gastroenterology Unit, Girona, Spain;(20)Hospital Universitario Donostia- Instituto Biodonostia, Gastroenterology Unit, San Sebastián, Spain;(21)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(22)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(23)Hospital Universitario Virgen de las Nieves, Gastroenterology Unit, Granada, Spain;(24)Complejo Hospitalario Universitario A Coruña, Gastroenterology Unit, A Coruña, Spain;(25)Hospital Universitario de Valdecilla and Instituto de Investigación Sanitaria Valdecilla IDIVAL, Gastroenterology Unit, Santander, Spain;(26)Hospital San Agustín, Gastroenterology Unit, Avilés, Spain;(27)Hospital Universitari Parc Taulí- Universitat Autònoma de Barcelona and CIBERehd, Gastroenterology Unit, Sabadell, Spain;(28)Consorci Sanitari de Terrassa, Gastroenterology Unit, Barcelona, Spain;(29)Hospital Universitario de Cáceres, Gastroenterology Unit, Cáceres, Spain;(30)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Alcorcón, Spain;(31)Hospital Universitario Infanta Cristina, Gastroenterology Unit, Madrid, Spain;(32)Hospital Virgen de la Luz, Gastroenterology Unit, Cuenca, Spain;(33)Hospital Universitario de Canarias, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(34)Hospital Universitario del Henares, Gastroenterology Unit, Madrid, Spain;(35)Hospital Sierrallana, Gastroenterology Unit, Torrelavega, Spain;(36)Hospital General Universitario de Alicante- CIBERehd and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Gastroenterology Unit, Alicante, Spain;(37)Hospital Universitario Arnau de Vilanova, Gastroenterology Unit, Lleida, Spain;on behalf of To-ReWard study group
P374: Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulasECCO'22Year: 2022
Authors: Lloyd, A.(1);Wilkinson, A.(2);Aleman Gonzalez, H.(2);Ramachandran, S.(2);Whitehead, E.(2);Pattinson, A.(2);Stamp, K.(2);Turnbull, J.(2);Talbot, A.(2);Sebastian, S.(2);
(1)Hull York Medical School, Department of Gastroenterology, Hull, United Kingdom;(2)Hull University Teaching Hospitals, IBD Unit- Department of Gastroenterology, Hull, United Kingdom;
P375: Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patientsECCO'22Year: 2022
Authors: Revés, J.(1);Morão, B.(1);Gomes, C.F.(1);Nascimento, C.(1);Abreu, N.(2);Gonçalves, T.C.(3);Castro, F.(3);Freitas, M.(3);Moreira, M.J.(3);Cotter, J.(3);Pereira, F.(4);Caldeira, A.(4);Sousa, R.(4);Coelho, R.(5);Macedo, G.(5);Macedo, C.(6);Ferreira, M.(6);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
(1)Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal;(2)Hospital Dr. Nélio Mendonça, Gastrenterology Department, Funchal, Portugal;(3)Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastrenterology Department, Guimarães/Braga, Portugal;(4)Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastrenterology Department, Castelo Branco, Portugal;(5)Centro Hospitalar de São João- Porto, Gastrenterology Department, Porto, Portugal;(6)Centro Hospitalar Universitário de Coimbra, Gastrenterology Department, Coimbra, Portugal;
P376: Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcomeECCO'22Year: 2022
Authors: Wiken, T.(1,2);Høivik, M.L.(1,2);Buer, L.(1);Bolstad, N.(3);Moum, B.A.(1,2);Medhus, A.W.(1);
(1)Oslo University Hospital, Departement of Gastroenterology, Oslo, Norway;(2)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(3)Oslo University Hospital, Departement of Medical Biochemistry, Oslo, Norway;
P377: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE studyECCO'22Year: 2022
Authors: Allez, M.(1);Lewis, J.D.(2);Hanauer, S.B.(3);Danese, S.(4);Irving, P.M.(5,6);Gasink, C.(7);Hoops, T.(8);Izanec, J.L.(7);Ma, T.(7);Loftus- Jr., E.V.(9);Scherl, E.J.(10);Panaccione, R.(11);Sandborn, W.J.(12);Sands, B.E.(13);
(1)Hôpital Saint-Louis- Assistance Publique-Hôpitaux de Paris AP-HP- INSERM U1160 and Université de Paris, Gastroenterology Department, Paris, France;(2)Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia, United States;(3)Northwestern University Feinberg School of Medicine, Department of Gastroenterology, Chicago, United States;(4)IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)Guy’s and Saint Thomas’ Hospitals NHS Trust, Department of Gastroenterology, London, United Kingdom;(6)King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom;(7)Janssen Scientific Affairs- LLC, Immunology, Horsham, United States;(8)Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States;(9)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(10)New York Presbyterian Hospital Weill Cornell Medicine, Weill Department of Medicine, New York, United States;(11)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(12)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(13)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
P378: Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE OpenECCO'22Year: 2022
Authors: Allegretti, J.R.(1);Gecse, K.B.(2);Chiorean, M.V.(3);Argollo, M.(4);Guo, X.(5);Lawendy, N.(5);Su, C.(5);Mundayat, R.(6);Paulissen, J.(6);Salese, L.(5);Irving, P.M.(7);
(1)Brigham and Women's Hospital, Division of Gastroenterology- Hepatology and Endoscopy, Boston- MA, United States;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)-, Swedish Medical Center, Seattle- WA, United States;(4)Federal University of São Paulo, Department of Gastroenterology, São Paulo, Brazil;(5)-, Pfizer Inc, Collegeville- PA, United States;(6)-, Pfizer Inc, New York- NY, United States;(7)Guy’s and St Thomas’ Hospital, IBD Unit, London, United Kingdom;
P379: Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?ECCO'22Year: 2022
Authors: Doherty, J.(1);Stack, R.(1);Fennessy, A.(1);Cullen, G.(1);Mulcahy, H.(1);Sheridan, J.(1);Kevans, D.(1);Doherty, G.(1);
(1)Centre for Colorectal Disease- St Vincent’s University Hospital & School of Medicine- University College Dublin, Gastroenterology, Dublin, Ireland;
P380: Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Feagan, B.G.(1);Colombel, J.F.(2);Panaccione, R.(3);Schreiber, S.(4);Ferrante, M.(5);Kamikozuru, K.(6);Lee, W.J.(7);Griffith, J.(7);Kligys, K.(7);Kalabic, J.(8);Chen, N.(7);Dubinsky, M.(2);
(1)Western University- Alimentiv Inc., n/a, London, Canada;(2)Icahn School of Medicine at Mt. Sinai, n/a, New York, United States;(3)University of Calgary, n/a, Calgary, Canada;(4)University Hospital Schleswig-Holstein, n/a, Kiel, Germany;(5)University Hospital Leuven, n/a, Leuven, Belgium;(6)Hyogo College of Medicine, n/a, Nishinomiya, Japan;(7)AbbVie Inc., n/a, North Chicago, United States;(8)AbbVie Deutschland GmbH & Co. KG, n/a, Ludwigshafen, Germany;
